The first patent application on the basic concept of PexyEazy® is accepted in USA, Japan, Singapore, Russia, South Africa, Israel and China. The international patent applications in Canada, Brazil, EU, India and Australia are still pending. International patent application based on the second patent is also filed in Canada, USA, Brazil, EU, South Africa, Russia, […]
First PexyEazy® procedure on human, as the first patient participated in the SCI-Pex study, a safety and feasibility study on PexyEazy®. A total of 35 patients will be included in the SCI-Pex study at two sites in Sweden.
Developeration AB was awarded “Seal of Excellence” by the European Commission as part of the application for Horizon EIC 2022 Accelerator grant. Our application was scored as a high-quality project proposal in a highly competitive evaluation process. We were invited for interviews this time, but unfortunately did we not get the grant.
Developeration AB was awarded by the Scandinavian Business Awards as the “Most Innovative Operation Research & Development Company – Sweden”. https://www.eubusinessnews.com/winners/developeration-ab/
ALMI Invest, STOAF, Rentability AB, Adiuvero AB and GAEU Venture AB invest I Developeration AB’s second investment round, in total 11,5 MSEK.
Developeration has been acknowledged as the “Best Medical Devices Developer – Scandinavia” by GHP, Global Health and Pharmacy, a global information sharing platform. https://www.ghp-news.com/winners-list/?award=11481-2021
Developeration AB is accepted to the EIT Health Investor Network as a GOLD Company.
A second patent application is filed directly as a EU-patent.
Developeration has been acknowledged as the “Most innovative medical devices developer – Scandinavia” by GHP, Global Health and Pharmacy, a global information sharing platform. https://www.ghp-news.com/winners/developeration-ab/
2020-09-15 ALMI Invest and STOAF, invest in Developeration AB, in total 4,4MSEK. https://stoaf.se/2020/09/15/stoaf-invests-in-developerations-innovative-surgical-device/